Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers

MUC1 aptamer-functionalized PLA-PEG nanocarriers at various w/w ratios (polymer to doxorubicin weight ratio) were prepared by a double emulsion method. Physiochemical properties, encapsulation efficiency (EE), loading content (LC) and in vitro release kinetics of DOX were assessed. Furthermore, cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahrad, Shima, Rajabi, Mohammad, Javadi, Hamidreza, Karimi Zarchi, Ali Akbar, Darvishi, Mohammad Hasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933396/
https://www.ncbi.nlm.nih.gov/pubmed/35304550
http://dx.doi.org/10.1038/s41598-022-08759-z
_version_ 1784671641655050240
author Shahrad, Shima
Rajabi, Mohammad
Javadi, Hamidreza
Karimi Zarchi, Ali Akbar
Darvishi, Mohammad Hasan
author_facet Shahrad, Shima
Rajabi, Mohammad
Javadi, Hamidreza
Karimi Zarchi, Ali Akbar
Darvishi, Mohammad Hasan
author_sort Shahrad, Shima
collection PubMed
description MUC1 aptamer-functionalized PLA-PEG nanocarriers at various w/w ratios (polymer to doxorubicin weight ratio) were prepared by a double emulsion method. Physiochemical properties, encapsulation efficiency (EE), loading content (LC) and in vitro release kinetics of DOX were assessed. Furthermore, cytotoxicity and antitumor activity of prepared PLA-PEG-Apt/DOX NPs at w/w ratio 10:1 were evaluated by MTT assay and flow cytometry against MUC1-overexpressing A-549 cell line. Targeted nanocarriers (PLA-PEG-Apt/DOX NPs at w/w ratio 10:1) induced higher apoptosis rate (36.3 ± 3.44%) for 24 h in MUC1 positive A-549 cancer cells in compare to non-targeted form (PLA-PEG/DOX NPs at w/w ratio 10:1, 11.37 ± 1.65%) and free DOX (4.35 ± 0.81%). In other word, the percentage of cell death in A-549 lung cancer cells treated with PLA-PEG-Apt/DOX NPs at w/w ratio 10:1 is 3.19 and 8.34 fold higher than in non-targeted form and Free DOX treated cancer cells, respectively. Therefore, PLA-PEG-Apt/DOX NPs might be considered a promising drug delivery system for targeted drug delivery towards MUC1-overexpressing tumors cells.
format Online
Article
Text
id pubmed-8933396
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89333962022-03-28 Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers Shahrad, Shima Rajabi, Mohammad Javadi, Hamidreza Karimi Zarchi, Ali Akbar Darvishi, Mohammad Hasan Sci Rep Article MUC1 aptamer-functionalized PLA-PEG nanocarriers at various w/w ratios (polymer to doxorubicin weight ratio) were prepared by a double emulsion method. Physiochemical properties, encapsulation efficiency (EE), loading content (LC) and in vitro release kinetics of DOX were assessed. Furthermore, cytotoxicity and antitumor activity of prepared PLA-PEG-Apt/DOX NPs at w/w ratio 10:1 were evaluated by MTT assay and flow cytometry against MUC1-overexpressing A-549 cell line. Targeted nanocarriers (PLA-PEG-Apt/DOX NPs at w/w ratio 10:1) induced higher apoptosis rate (36.3 ± 3.44%) for 24 h in MUC1 positive A-549 cancer cells in compare to non-targeted form (PLA-PEG/DOX NPs at w/w ratio 10:1, 11.37 ± 1.65%) and free DOX (4.35 ± 0.81%). In other word, the percentage of cell death in A-549 lung cancer cells treated with PLA-PEG-Apt/DOX NPs at w/w ratio 10:1 is 3.19 and 8.34 fold higher than in non-targeted form and Free DOX treated cancer cells, respectively. Therefore, PLA-PEG-Apt/DOX NPs might be considered a promising drug delivery system for targeted drug delivery towards MUC1-overexpressing tumors cells. Nature Publishing Group UK 2022-03-18 /pmc/articles/PMC8933396/ /pubmed/35304550 http://dx.doi.org/10.1038/s41598-022-08759-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Shahrad, Shima
Rajabi, Mohammad
Javadi, Hamidreza
Karimi Zarchi, Ali Akbar
Darvishi, Mohammad Hasan
Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers
title Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers
title_full Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers
title_fullStr Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers
title_full_unstemmed Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers
title_short Targeting lung cancer cells with MUC1 aptamer-functionalized PLA-PEG nanocarriers
title_sort targeting lung cancer cells with muc1 aptamer-functionalized pla-peg nanocarriers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933396/
https://www.ncbi.nlm.nih.gov/pubmed/35304550
http://dx.doi.org/10.1038/s41598-022-08759-z
work_keys_str_mv AT shahradshima targetinglungcancercellswithmuc1aptamerfunctionalizedplapegnanocarriers
AT rajabimohammad targetinglungcancercellswithmuc1aptamerfunctionalizedplapegnanocarriers
AT javadihamidreza targetinglungcancercellswithmuc1aptamerfunctionalizedplapegnanocarriers
AT karimizarchialiakbar targetinglungcancercellswithmuc1aptamerfunctionalizedplapegnanocarriers
AT darvishimohammadhasan targetinglungcancercellswithmuc1aptamerfunctionalizedplapegnanocarriers

Ejemplares similares